1. Abstract
Background Previously, studies have indicated that high-density cholesterol (HDL-C) levels are associated with lower risk of cardiovascular disease. However, this has been challenged in recent years.
Method This cross-sectional study was conducted on data from the National Health and Nutrition Examination Survey 2011-2020. There were total of 15232 out of 45462 individuals who were age >40 years old, not missing HDL-C levels and not missing stroke data. The independent variable was HDL-Cholesterol. The outcome variable was stroke. We used multivariate logistic regression models to assess the relationship between stroke and HDL-C in three models consisting of the following explanatory variables: 1. HDL-C alone (unadjusted model), 2. HDL-C and non-modifiable risk factors (age, sex and race), 3. HDL-C, non-modifiable, and modifiable risk factors [hypertension, diabetes and smoking status] risk factors. We also conducted analyses stratified by sex and race.
Results HDL-C categories 40-59 mg/dl (unadjusted model- 0.759, CI: 0.639, 0.901; non-modifiable risk factors adjusted- 0.668, CI: 0.558, 0.798) and 60-79 mg/dl (unadjusted model- 0.733, CI: 0.598, 0.898; non-modifiable risk factors adjusted- 0.565, CI: 0.455, 0.701) had significantly lower risk of stroke relative to HDL-C category <40 mg/dl. But when adjusted for modifiable risk factors, risk of stroke HDL-C categories 40-59 mg/dl and 60-79 mg/dl categories were not significantly different from the HDL-C <40 mg/dl category. The risk of stroke HDL-C categories 80-89 mg/dl and >90 mg/dl categories were not significantly different from the HDL-C <40 mg/dl category in all models. In stratified analyses, HDL-C was significantly inversely associated with the risk of stroke in male gender and in non-Hispanic White race.
Conclusion Our study reveals various inverse relationship between HDL-C and risk of stroke. These findings suggest that relevant levels of HDL-C may be beneficial in preventing stroke in the absence of modifiable risk-factors.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this research.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We did not required IRB approval.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All datasets are available on the National Health and Nutrition Examination Survey website.
